Armistice Capital, LLC 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 9:37 pm Sale | 2025-12-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 2,764,000 4.820% | -72,000 (-2.54%) | Filing |
| 2025-11-14 6:27 pm Sale | 2025-09-30 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 2,836,000 5.060% | -1,976,000 (-41.06%) | Filing |
| 2025-05-15 3:18 pm Purchase | 2025-03-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 5,196,000 9.280% | 360,000 (+7.44%) | Filing |
| 2025-02-14 5:20 pm Sale | 2024-12-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 4,836,000 8.760% | -260,000 (-5.10%) | Filing |
| 2024-11-14 5:14 pm Purchase | 2024-09-30 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 5,096,000 9.250% | 446,000 (+9.59%) | Filing |
| 2024-02-14 2:33 pm Purchase | 2023-12-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 4,650,000 8.510% | 294,000 (+6.75%) | Filing |
| 2023-02-14 1:33 pm Purchase | 2022-12-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 4,356,000 8.060% | 220,000 (+5.32%) | Filing |
| 2022-02-14 7:03 pm Purchase | 2021-12-31 | 13G | SUPERNUS PHARMACEUTICALS INC C SUPN | Armistice Capital, LLC | 4,136,000 7.800% | 1,016,000 (+32.56%) | Filing |